Cargando…

The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological Study

INTRODUCTION: Saxagliptin is a potent, reversible inhibitor of dipeptidyl peptidase-4 that is indicated for the treatment of type 2 diabetes. The DIAPAZON study was a multicenter observational study intended to document the effectiveness, safety and patterns of saxagliptin use in France, including t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balkau, Beverley, Charbonnel, Bernard, Penfornis, Alfred, Chraibi, Nora, Lahouegue, Amir, Faure, Céline, Thomas-Delecourt, Florence, Detournay, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630565/ https://www.ncbi.nlm.nih.gov/pubmed/28948519 http://dx.doi.org/10.1007/s13300-017-0311-2

Ejemplares similares

Persistence with Insulin Therapy in Patients with Type 2 Diabetes in France: An Insurance Claims Study
por: Roussel, Ronan, et al.
Publicado: (2016)

Uso del diapazón como auxiliar diagnóstico en la polineuropatía diabética
por: Rodríguez Alfonsín, Enrique
Publicado: (1994)

Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis
por: Charbonnel, Bernard, et al.
Publicado: (2017)

Persistence with Basal Insulin and Frequency of Hypoglycemia Requiring Hospitalization in Patients with Type 2 Diabetes
por: Roussel, Ronan, et al.
Publicado: (2020)

Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010)

Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France
por: Detournay, Bruno, et al.
Publicado: (2020)

The Effectiveness of an App (Insulia) in Recommending Basal Insulin Doses for French Patients With Type 2 Diabetes Mellitus: Longitudinal Observational Study
por: Nevoret, Camille, et al.
Publicado: (2023)

The association between asthma control, health care costs, and quality of life in France and Spain
por: Doz, Marianne, et al.
Publicado: (2013)

Comparison of charges and resource use associated with saxagliptin and sitagliptin
por: Vaidya, Varun, et al.
Publicado: (2016)

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
por: Pollack, Pia S., et al.
Publicado: (2017)

Evaluation of drug interactions of saxagliptin with sildenafil in healthy volunteers
por: Mansour, Rania Y., et al.
Publicado: (2022)

Factors associated with psychological and behavioral functioning in people with type 2 diabetes living in France
por: Boini, Stephanie, et al.
Publicado: (2010)

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
por: Neumiller, Joshua J.
Publicado: (2014)

Hospital stays and costs of telemedical monitoring versus standard follow-up for diabetic foot ulcer: an open-label randomised controlled study
por: Dardari, Dured, et al.
Publicado: (2023)

Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes
por: Sharma, Morali D
Publicado: (2010)

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
por: Cobble, Michael E, et al.
Publicado: (2012)

Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Kulasa, Kristen, et al.
Publicado: (2010)

Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients
por: Konya, Hiroyuki, et al.
Publicado: (2014)

Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in Argentina
por: Elgart, Jorge F, et al.
Publicado: (2013)

Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
por: Ott, Christian, et al.
Publicado: (2014)

Utility of Saxagliptin in the Treatment of Type 2 Diabetes: Review of Efficacy and Safety
por: Jain, Rajeev
Publicado: (2015)

Saxagliptin Restores Vascular Mitochondrial Exercise Response in the Goto-Kakizaki Rat
por: Keller, Amy C., et al.
Publicado: (2015)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
por: Minze, Molly G., et al.
Publicado: (2013)

Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor
por: Wang, Aiying, et al.
Publicado: (2012)

Assessing Patient Perceptions and Experiences of Paracetamol in France: Infodemiology Study Using Social Media Data Mining
por: Schück, Stéphane, et al.
Publicado: (2021)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz, Baptist
Publicado: (2010)

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
por: Panagoulias, George S, et al.
Publicado: (2014)

Clinical outcomes, not clinical utility, should be the major consideration for saxagliptin with or without metformin
por: Doggrell, Sheila A
Publicado: (2014)

Saxagliptin Efficacy and Safety in Patients With Type 2 Diabetes and Moderate Renal Impairment
por: Perl, Shira, et al.
Publicado: (2016)

Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients
por: Garg, Rajesh, et al.
Publicado: (2017)

Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study
por: Balkau, Beverley, et al.
Publicado: (2010)

Epidemiology and Clinical Burden of Meningococcal Disease in France: Scoping Review
por: Baloche, Alexiane, et al.
Publicado: (2023)

Comment on: Park et al. Association of Serum Ferritin and the Development of Metabolic Syndrome in Middle-Aged Korean Men: A 5-Year Follow-up Study. Diabetes Care 2012;35:2521–2526
por: Fumeron, Frédéric, et al.
Publicado: (2012)

Disability-adjusted life years lost due to diabetes in France, Italy, Germany, Spain, and the United Kingdom: a burden of illness study
por: Darbà, Josep, et al.
Publicado: (2015)

Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
por: Dave, Darshan J.
Publicado: (2011)

Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
por: Shubrook, Jay, et al.
Publicado: (2011)

Effect of saxagliptin on the expression of HIF-1α in the liver of diabetic rats with fatty liver
por: Zhao, Qian, et al.
Publicado: (2018)

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
por: Koyani, Chintan N., et al.
Publicado: (2018)

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
por: Yu, Huan, et al.
Publicado: (2017)

Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials
por: Sjöstrand, Mikaela, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gg8i3cmolgoj807c3v9a018epe